Notification Versus Authorization Changes: How Guatemala Classifies Registration Modifications

1. Key takeaways

Guatemala splits changes to a sanitary registration into two procedures: notification only (notificación) and prior authorisation (autorización). Article 6 of NT 37 confirms that the dichotomy exists, but does not label each category in its body text; Article 7 of NT 40, by contrast, sets out an explicit list on the reagent side, with only one notification item (a change of secondary packaging) and thirteen authorisation items (including change of holder, change of the manufacturing entity, change of distributor, packaging changes, addition of an alternate plant, excipient changes and specification changes). For a device company the asymmetry matters: the device standard names the two tracks but leaves the classification of individual changes to be worked out, while the reagent standard hands over a ready-made list that can be used as a reference map. The safe operating assumption, until the reviewing department says otherwise, is that anything touching the product’s identity, origin or quality belongs on the authorisation track.

2. Legal basis

The thirteen authorisation items listed in Article 7 of NT-40 are: change of holder, change of distributor, change of the domestic legal representative, change and extension of specifications, change of product name, change of the holder’s trade name, cancellation of the registration, change of the product’s responsible professional, change of primary packaging, change of the manufacturing entity, addition of an alternate plant, change of excipients, and change of specifications.

3. Expert insights

Insight 1: The reagent-side list is clearer than the device-side text and can serve as a reference. Article 7 of NT-40 sets the two classes of changes out side by side, while Article 6 of NT-37 merely confirms that the dichotomy exists without labelling each item. A device project that must decide which class a change belongs to can borrow the listing logic of the reagent side as a first approximation, but the binding conclusion rests with the reviewing practice of DRCPFA. This two-step approach, list first and confirm second, keeps device projects from guessing blind while still respecting the fact that the device standard itself did not draw the map, and that only the department’s reading settles borderline cases.

Insight 2: Anything touching the entity, the name or the packaging specifications lands in the authorisation class. The thirteen authorisation items in Article 7 of NT-40 cover the holder, the distributor, the legal representative, the product name, the trade name, the manufacturing entity, the alternate plant, the primary packaging, the specifications and the excipients, in other words every element that can affect the identification, the origin or the quality of the product. Only the change of secondary packaging is placed in the notification class, precisely because it does not touch the product itself. The pattern behind the list is easy to internalise: if a proposed change would alter what the product is, who stands behind it, or what it is made of and packed in, plan for an authorisation, not a notification.

Insight 3: The cost of a classification error concentrates at renewal. Article 8 of NT-40 provides that if the reagent carries changes that were never authorised, renewal cannot follow the simplified path and the full dossier under Article 4 must be submitted again. NT-37 has a parallel structure in Article 9: where changes exist, the documents required under Article 5 must be provided. Treating an authorisation-class change as if it were a notification saves effort in the short term and repays it with interest at renewal, when the entire dossier must be rebuilt. The renewal moment is therefore where every shortcut taken in change management becomes visible and expensive at once.

Insight 4: RTCA 11.03.59:18 supplies the dichotomy at the regional level. Annex 1 of this regional technical regulation divides post-market changes into those requiring prior approval and those requiring notification, and it entered into force in Guatemala on 2022-01-03. Its subject matter is medicines, but its structure matches Article 7 of NT-40, so it works as a reference for understanding the national classification logic. Reading the regional instrument alongside the national standards gives a compliance team two consistent descriptions of the same dichotomy, which is useful when training staff or defending a classification internally before anything is filed.

4. Practical recommendations

• Before filing any change, classify it: anything involving entities, names, packaging specifications or the manufacturing source is prepared on the authorisation track.
• Only a change of secondary packaging can be considered for the notification track, and even then the classification should be confirmed with DRCPFA first.
• Device projects should use the listing logic of Article 7 of NT-40 as a reference, while treating the reviewing practice as the deciding voice.
• Maintain a change ledger recording the class, the approval number and the date of every change, ready to be called upon at renewal.
• Before renewal, audit the ledger for unauthorised changes to avoid being pushed back to a full dossier submission.

5. Verification checklist

• □ Every change has been classified as notification or authorisation
• □ Changes involving entities, names or specifications are prepared as authorisations
• □ The change ledger records the class and the approval date of each change
• □ The ledger has been audited for unauthorised changes before renewal
• □ The dichotomy of Annex 1 of RTCA 11.03.59:18 has been used as a reference

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com